



# Role of Chloroquine and Hydroxychloroquine in the Treatment of COVID19

Nisreen H Meiqal<sup>1</sup>, Salah M Bensaber<sup>1</sup>, Mousa I Jaeda<sup>1</sup>, Anton Hermann<sup>2</sup> and Abdul M Gbaj<sup>1\*</sup>

<sup>1</sup>Department of Medicinal Chemistry, Faculty of Pharmacy, University of Tripoli, Libya

<sup>2</sup>Department of Biosciences, University of Salzburg, Salzburg, Austria

\*Corresponding author: Abdul M Gbaj, Associate Professor of Genetics and Biochemistry, Department of Medicinal Chemistry, Faculty of Pharmacy, University of Tripoli, Libya

Received: 📅 June 16, 2020

Published: 📅 June 23, 2020

**Abbreviations:** (WHO) World Health Organization; (FDA) Food and Drug Administration; (EMA) European Medicines Agency

## Introduction


Chloroquine was discovered in 1934 by Hans Andersag (German scientist) while he was working for the Bayer Pharmaceutical Company, and this drug was initially called (Resochin) [1,2]. In 1945, the World Health Organization (WHO) recommended the use of chloroquine in the treatment of malaria, which was a deadly disease in many cases [3,4]. Both chloroquine and (safer analogue) with the chemical formula shown in Figure 1 are currently considered to be important drugs listed as anti-malaria agents according to the WHO, the US Food and Drug Administration (FDA), and the European Medicines Agency (EMA) [5,6]. Moreover, hydroxychloroquine is presently widely used to treat autoimmune diseases such as lupus and rheumatoid arthritis [7,8]. Both medications are considered safe drugs whose side effects are generally mild. However, their use must be subjected to strict rules, and self-treatment (without direct medical supervision) is not recommended due to their narrow therapeutic index [9,10].

## Anti-viral activity

*In vitro* antiviral activity of chloroquine has been identified since the late sixties as scientists were able to inhibit the growth of many different viruses by chloroquine and hydroxychloroquine [11]. More recently, the ability of both drugs to inhibit the growth of viruses from the corona family (2004), as well as later the Ebola virus were identified [12-15]. Subsequently, several *in vivo* experiments in mice were conducted to test the efficacy *in vitro* of both drugs to inhibit the growth of viruses. The experiments suggested that the drugs were effective against both corona (OC43) [16,17] and influenza (A H5N1), but lack activity against the Ebola virus [18,19]. In addition, many clinical studies were conducted to test the ability of both chloroquine and hydroxychloroquine to inhibit the growth of viruses [20,21]. These clinical studies indicate that no severe viral infection can be treated with chloroquine or hydroxychloroquine although a modest effect of chloroquine in treating human infection with chronic hepatitis C was reported [22].

## Antiviral activity against the emerging corona virus (SARS-CoV2)

After the emergence of the COVID-19 pandemic, many drugs and chemical compounds that inhibited viruses in the past were tested against SARS-CoV2 virus. Initially, *in vitro* investigation of chloroquine's ability to inhibit the emerging corona virus (SARS-CoV2) was reported in China (February 2020) indicating high activity [23,24]. These investigations were followed by several *in*



**Figure 1:** Chemical structure of chloroquine and hydroxychloroquine.

vitro and clinical studies that aimed to demonstrate the ability of chloroquine and hydroxychloroquine to inhibit SARS-CoV2 virus in China and some other countries [25-27].

Based on the results of these studies, the following statements can be concluded:

- a. Chloroquine and hydroxychloroquine exhibit good *in vitro* efficacy (anti SARS-CoV2) [25-27].
- b. More *in vivo* studies are required to determine the pharmacokinetic properties of Chloroquine and hydroxychloroquine as possible anti SARS-CoV2 drugs
- c. A variety of clinical studies are registered in various countries to test chloroquine and hydroxychloroquine ability to inhibit the emerging corona virus (SARS-CoV2) [28-31]. Accordingly, some specialized institutions in some countries and international consortia started to include chloroquine and hydroxychloroquine as part of their medical protocol to treat COVID19 patients. However, this initiation is regarded problematic due to the lack of proof of efficacy as well as fear of unexpected clinical side effects [32-34].
- d. Recently, clinical studies (multinational registry analysis) of the use of chloroquine and hydroxychloroquine with or without a macrolide (a class of natural products that consist of a large macrocyclic lactone ring with one or more deoxy sugars attached) for treatment of COVID-19 was reported based on COVID 19 patients hospitalized in different countries. The achieved results indicated lack of evidence of benefit of both medications to effectively treat COVID 19 patients. In addition, there was an associated increase of ventricular arrhythmias and a greater hazard for in-hospital death with COVID-19 [35-37].
- e. Based on the findings listed in point (4), the FDA warned against using of chloroquine and hydroxychloroquine outside the medical framework, the WHO suspended their clinical trials for safety reasons, and their use as part of the treatment protocols were later stopped by the French government.

## Conclusion

Chloroquine or its analogues appeared a hope for humanity in the treatment of the COVID-19 disease. Chloroquine is cheap and safe (if used under medical supervision), and early results of *in vitro* studies were promising. However, this initial achievement requires further investigation to verify the suitability and safety of their use. Currently, WHO does not recommend any specific antiretroviral drugs against SARS-CoV2, citing the lack of sufficient evidence to recommend any specific treatment that includes chloroquine or its analogues. To determine the efficacy of chloroquine or its analogues to treat COVID 19, it will be necessary to provide more financial support for the continuation of clinical trials.

## Acknowledgement

The authors gratefully acknowledge the technical support and valuable suggestions obtained from Ms Amira Abdul Gbaj (Novelien Zone, Tripoli, Libya).

## Reference

1. SĀi JM, Chong JL, Wellem TE (2011) Malaria drug resistance: new observations and developments. *Essays Biochem* 51: 137-160.
2. Pou S, Winter RW, Nilsen A, Kelly JX, Li Y et al. (2012) Sontochin as a Guide to the Development of Drugs against Chloroquine-Resistant Malaria. *Antimicrob Agents Chemother* 56(7): 3475-3480.
3. Beausoleil E (1984) A review of present antimalaria activities in Africa. *Bull. World Health Organ* 62: 13-17.
4. Okech BA, Existe A, Romain JR, Memnon G, Victor YS et al. (2015) Therapeutic Efficacy of Chloroquine for the Treatment of Uncomplicated *Plasmodium falciparum* in Haiti after Many Decades of its Use. *Am J Trop Med Hyg* 92(3): 541-545.
5. Mittal L, Zhang L, Feng R, Werth VP (2018) Antimalarial drug toxicities in patients with cutaneous lupus and dermatomyositis: a retrospective cohort study. *J Am Acad Dermatol* 78(1): 100-106.
6. Browning DJ (2014) Pharmacology of Chloroquine and Hydroxychloroquine. *Hydroxychloroquine and Chloroquine Retinopathy* 4: 35-63.
7. Smolen JS, LandewĀR, Breedveld FC, Buch M, Burmester G et al. (2014) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. *Ann Rheum Dis* 73(3): 492-509.
8. Urman A, Taklalsingh N, Sorrento C, McFarlane IM (2018) Inflammation beyond the Joints: Rheumatoid Arthritis and Cardiovascular Disease. *Scifed J Cardiol* 2(3): 1000019.
9. Savage DE, Plotnik R, Wozniak RA (2020) Short-term high-dose hydroxychloroquine corneal toxicity. *Am J Ophthalmol Case Rep* 18: 100713.
10. Motarjemizadeh Q, Aidenloo NS, Abbaszadeh M (2016) Detection of Hydroxychloroquine Retinal Toxicity by Automated Perimetry in 60 Rheumatoid Arthritis Patients With Normal Fundoscopic Findings. *Glob J Health Sci* 8(3): 59-64.
11. Dyal J, Gross R, Kindrachuk J, Johnson RF, Olinger GG et al. (2017) Middle East Respiratory Syndrome and Severe Acute Respiratory Syndrome: Current Therapeutic Options and Potential Targets for Novel Therapies. *Drugs* 77(18): 1935-1966.
12. Zimmermann P, Curtis N (2020) Coronavirus Infections in Children Including COVID-19: An Overview of the Epidemiology Clinical Features Diagnosis Treatment and Prevention Options in Children. *Pediatr Infect Dis J* 39(5): 355-368.
13. Chan JFW, Lau SKP, To KKW, Cheng VCC, Woo PCY et al. (2015) Middle East Respiratory Syndrome Coronavirus: Another Zoonotic Betacoronavirus Causing SARS-Like Disease. *Clin Microbiol Rev* 28(2): 465-522.
14. Dhama K, Karthik K, Khandia R, Chakraborty S, Munjal A, et al. (2018) Advances in Designing and Developing Vaccines Drugs and Therapies to Counter Ebola Virus. *Front Immunol* 9: 1803.
15. Xiao JH, Rijal P, Schimanski L, Tharkeshwar AK, Wright E, et al. (2018) Characterization of Influenza Virus Pseudotyped with Ebolavirus Glycoprotein. *J Virol* 92(4): e00941-e009417.
16. Wang S, Zhang L, Zhang R, Chi X, Yang Z, (2018) Identification of two residues within the NS1 of H7N9 influenza A virus that critically affect the protein stability and function. *Vet Res* 49: 98.

17. Liu G, Park HS, Pyo HM, Liu Q, Zhou Y (2015) Influenza A Virus Panhandle Structure Is Directly Involved in RIG-I Activation and Interferon Induction. *J Virol* 89(11): 6067-6079.
18. Dhama K, Karthik K, Khandia R, Chakraborty S, Munjal A, et al. (2018) Advances in Designing and Developing Vaccines, Drugs, and Therapies to Counter Ebola Virus. *Front Immunol* 9: 1803.
19. Dowall SD, Bosworth A, Watson R, Bewley K, Taylor I, et al. (2015) Chloroquine inhibited Ebola virus replication in vitro but failed to protect against infection and disease in the in vivo guinea pig model. *J Gen Virol* 96(12): 3484-3492.
20. Savarino A, Boelaert JR, Cassone A, Majori G, Cauda R (2003) Effects of chloroquine on viral infections: an old drug against today's diseases. *Lancet Infect Dis* 3(11): 722-727.
21. Delvecchio R, Higa LM, Pezzuto P, Valadão AL, Garcez PP, et al. (2016) Chloroquine, an Endocytosis Blocking Agent, Inhibits Zika Virus Infection in Different Cell Models. *Viruses* 8(12): 322.
22. Rodrigo C, Fernando SD (2020) Rajapakse S Clinical evidence for repurposing chloroquine and hydroxychloroquine as antiviral agents: a systematic review. *Clin Microbiol Infect.*
23. Wang M, Cao R, Zhang L, Yang X, Liu J, et al. (2020) Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. *Cell Res* 30(3): 269-271.
24. Akçelik YS, Acanal S (2020) Antiviral treatment of COVID-19. *Turk J Med Sci* 50(SI-1): 611-619.
25. Felsenstein S, Herbert JA, McNamara PS, Hedrich CM (2020) COVID-19: Immunology and treatment options. *Clin Immunol* 215: 108448.
26. Roustit M, Guilhaumou R, Molimard M, Drici MD, et al. (2020) Chloroquine and hydroxychloroquine in the management of COVID-19: Much kerfuffle but little evidence. *Therapie.*
27. Quiros RE, Biasiotto G, Magro P, Zanella I (2020) The possible mechanisms of action of 4-aminoquinolines chloroquine/hydroxychloroquine against Sars-Cov-2 infection (COVID-19): A role for iron homeostasis. *Pharmacol Res* 2020; 158: 104904.
28. Huang J, Song W, Huang H, Sun Q (2020) Pharmacological Therapeutics Targeting RNA-Dependent RNA Polymerase Proteinase and Spike Protein: From Mechanistic Studies to Clinical Trials for COVID-19. *J Clin Med* 9(4):1131.
29. Abd El-Aziz TM, Stockand JD (2020) Recent progress and challenges in drug development against COVID-19 coronavirus SARS-CoV-2 - an update on the status. *Infect Genet Evol* 83: 104327.
30. Tobaiqy M, Qashqary M, Al Dahery S, Mujallad A, Hershan A, et al. Therapeutic management of patients with COVID-19: a systematic review 2(3): 10006.
31. Zhang J, Xie B, Hashimoto K (2020) Current status of potential therapeutic candidates for the COVID-19 crisis. *Brain Behav. Immun* 87: 59-73.
32. Abd El-Aziz TM, Stockand JD (2020) Recent progress and challenges in drug development against COVID-19 coronavirus (SARS-CoV-2) - an update on the status. *Infect Genet Evol* 83: 104327.
33. Yan Y, Shin WI, Pang YX, Meng Y, Lai J, et al. (2020) The First 75 Days of Novel Coronavirus (SARS-CoV-2) Outbreak: Recent Advances, Prevention, and Treatment. *Int J Environ Res Public Health* 17(7): 2323.
34. Tobaiqy M, Qashqary M, Al Dahery S, Mujallad A, Hershan A, et al. (2020) Therapeutic management of patients with COVID-19: a systematic review 2(3): 100061.
35. Mehra MR, Desai SS, Ruschitzka F, Patel AN (2020) Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. *Lancet.*
36. Roustit M, Guilhaumou R, Molimard M, Drici MD, Laporte S, et al. (2020) Chloroquine and hydroxychloroquine in the management of COVID-19: Much kerfuffle but little evidence. *Therapie.*
37. Carrière F, Longhi S, Record M (2020) The endosomal lipid bis(monoacylglycerol) phosphate as a potential key player in the mechanism of action of chloroquine against SARS-COV-2 and other enveloped viruses hijacking the endocytic pathway. *Biochimie.*



This work is licensed under Creative Commons Attribution 4.0 License

To Submit Your Article Click Here:

[Submit Article](#)

DOI: [10.32474/LOJMS.2020.05.000209](https://doi.org/10.32474/LOJMS.2020.05.000209)



### Lupine Online Journal of Medical Sciences

#### Assets of Publishing with us

- Global archiving of articles
- Immediate, unrestricted online access
- Rigorous Peer Review Process
- Authors Retain Copyrights
- Unique DOI for all articles